Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin in Enzalutamide-Refractory CRPC
NCT03275857Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Sep 2018
- Primary completion
- Jul 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cisplatin micelle injection (HA132) in prostate cancer (PCa), sponsored by University of Rochester. Primary endpoints: Response to dosing differences of Cisplatin from lab and scan results at 2 years and Toxicity observed with dosing differences of Cisplatin at 2 years. Started Sep 2018; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03275857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275857.